<code id='73172880BD'></code><style id='73172880BD'></style>
    • <acronym id='73172880BD'></acronym>
      <center id='73172880BD'><center id='73172880BD'><tfoot id='73172880BD'></tfoot></center><abbr id='73172880BD'><dir id='73172880BD'><tfoot id='73172880BD'></tfoot><noframes id='73172880BD'>

    • <optgroup id='73172880BD'><strike id='73172880BD'><sup id='73172880BD'></sup></strike><code id='73172880BD'></code></optgroup>
        1. <b id='73172880BD'><label id='73172880BD'><select id='73172880BD'><dt id='73172880BD'><span id='73172880BD'></span></dt></select></label></b><u id='73172880BD'></u>
          <i id='73172880BD'><strike id='73172880BD'><tt id='73172880BD'><pre id='73172880BD'></pre></tt></strike></i>

          explore

          explore

          author:comprehensive    Page View:9372
          Vertex Pharmaceuticals Inc. building
          Craig F. Walker/The Boston Globe

          Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease. 

          The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

          advertisement

          “The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          Amylyx ALS drug failure raises questions and concerns
          Amylyx ALS drug failure raises questions and concerns

          Relyvrio,anALSdrugmadebyAmylyxPharmaceuticals,failedtobeatplaceboinakeyclinicaltrial.AmylyxPharmaceu

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          Sen. Paul opposes bill to ban Chinese biotechs

          Sen.RandPaul(R-Ky.)WinMcNamee/GettyImagesWASHINGTON—ASenatepanelWednesdaypassedabillaimedatpreventin